A Philosophical Framework for Integrating Systems Pharmacology Models Into Pharmacometrics

Overview

Journal CPT Pharmacometrics Syst Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2016 Nov 19

PMID 27863137

Citations 3

Authors

S B Duffull

Affiliations

Soon will be listed here.

Abstract

The framework for systems pharmacology style models does not naturally sit with the usual scientific dogma of parsimony and falsifiability based on deductive reasoning. This does not invalidate the importance or need for overarching models based on pharmacology to describe and understand complicated biological systems. However, it does require some consideration on how systems pharmacology fits into the overall scientific approach.

Citing Articles

Towards a comprehensive assessment of QSP models: what would it take?.

Androulakis I J Pharmacokinet Pharmacodyn. 2022; 51(5):521-531.

PMID: 35962928 PMC: 9922790. DOI: 10.1007/s10928-022-09820-0.

Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network.

Cucurull-Sanchez L, Chappell M, Chelliah V, Cheung S, Derks G, Penney M CPT Pharmacometrics Syst Pharmacol. 2019; 8(5):259-272.

PMID: 30667172 PMC: 6533407. DOI: 10.1002/psp4.12381.

Perspective on the State of Pharmacometrics and Systems Pharmacology Integration.

Trame M, Riggs M, Biliouris K, Marathe D, Mettetal J, Post T CPT Pharmacometrics Syst Pharmacol. 2018; 7(10):617-620.

PMID: 29761892 PMC: 6202472. DOI: 10.1002/psp4.12313.

References

Wajima T, Isbister G, Duffull S . A comprehensive model for the humoral coagulation network in humans. Clin Pharmacol Ther. 2009; 86(3):290-8. DOI: 10.1038/clpt.2009.87. View

Dokoumetzidis A, Aarons L . Proper lumping in systems biology models. IET Syst Biol. 2009; 3(1):40-51. DOI: 10.1049/iet-syb:20070055. View

Ahn J, Birnbaum A, Brundage R . Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses. J Pharmacokinet Pharmacodyn. 2005; 32(5-6):703-18. DOI: 10.1007/s10928-005-0083-6. View

Greenland S . Induction versus Popper: substance versus semantics. Int J Epidemiol. 1998; 27(4):543-8. DOI: 10.1093/ije/27.4.543. View

Mager D, Jusko W . General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2002; 28(6):507-32. DOI: 10.1023/a:1014414520282. View

Dua P, Hawkins E, van der Graaf P . A Tutorial on Target-Mediated Drug Disposition (TMDD) Models. CPT Pharmacometrics Syst Pharmacol. 2015; 4(6):324-37. PMC: 4505827. DOI: 10.1002/psp4.41. View

Bies R, Cook S, Duffull S . The pharmacometrician's dilemma: the tension between mechanistic and empirical approaches in mathematical modelling and simulation - a continuation of the age-old dispute between rationalism and empiricism?. Br J Clin Pharmacol. 2016; 82(3):580-2. PMC: 5338100. DOI: 10.1111/bcp.13040. View

Kitano H . Computational systems biology. Nature. 2002; 420(6912):206-10. DOI: 10.1038/nature01254. View

Motulsky H, Mahan L . The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol. 1984; 25(1):1-9. View

10.

van der Greef J, McBurney R . Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat Rev Drug Discov. 2005; 4(12):961-7. DOI: 10.1038/nrd1904. View

11.

Hill A . The mode of action of nicotine and curari, determined by the form of the contraction curve and the method of temperature coefficients. J Physiol. 1909; 39(5):361-73. PMC: 1533665. DOI: 10.1113/jphysiol.1909.sp001344. View

12.

Anderson B, Holford N . Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2007; 48:303-32. DOI: 10.1146/annurev.pharmtox.48.113006.094708. View

13.

Kitano H . Systems biology: a brief overview. Science. 2002; 295(5560):1662-4. DOI: 10.1126/science.1069492. View

14.

Ma P . Theoretical considerations of target-mediated drug disposition models: simplifications and approximations. Pharm Res. 2011; 29(3):866-82. DOI: 10.1007/s11095-011-0615-2. View

15.

Cao Y, Jusko W . Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn. 2014; 41(4):375-87. PMC: 4167346. DOI: 10.1007/s10928-014-9372-2. View

16.

Gulati A, Isbister G, Duffull S . Effect of Australian elapid venoms on blood coagulation: Australian Snakebite Project (ASP-17). Toxicon. 2012; 61:94-104. DOI: 10.1016/j.toxicon.2012.11.001. View

17.

Gulati A, Isbister G, Duffull S . Scale reduction of a systems coagulation model with an application to modeling pharmacokinetic-pharmacodynamic data. CPT Pharmacometrics Syst Pharmacol. 2014; 3:e90. PMC: 3910010. DOI: 10.1038/psp.2013.67. View

18.

Shivva V, Tucker I, Duffull S . An In Silico Knockout Model for Gastrointestinal Absorption Using a Systems Pharmacology Approach - Development and Application for Ketones. PLoS One. 2016; 11(9):e0163795. PMC: 5042539. DOI: 10.1371/journal.pone.0163795. View

19.

Lendrem D, Lendrem B, Rowland-Jones R, DAgostino F, Linsley M, Owen M . Teaching examples for the design of experiments: geographical sensitivity and the self-fulfilling prophecy. Pharm Stat. 2015; 15(1):90-2. DOI: 10.1002/pst.1723. View

20.

Sheiner L . Learning versus confirming in clinical drug development. Clin Pharmacol Ther. 1997; 61(3):275-91. DOI: 10.1016/S0009-9236(97)90160-0. View